ANTITUMOR ACTIVITY OF PI3K ANTAGONIST AEZS126*IN MODELS OF TRIPLE NEGATIVE BREAST CANCER

被引：0
|
作者：
Engel, J. B. [1 ]
Schmidt, H. [1 ]
Haeussler, S. [1 ]
Diessner, J. [1 ]
Hahne, J. [1 ]
Meyer, S. [1 ]
Wischhusen, J. [1 ]
Dietl, J. [1 ]
Hoenig, A. [1 ]
机构：
[1] Univ Wurzburg, Dept Obstet & Gynecol, Wurzburg, Germany
来源：
ANTICANCER RESEARCH | 2011年 / 31卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1967 / 1968
页数：2
相关论文
共 50 条
  • [1] Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer
    Jens C. Hahne
    Heike Schmidt
    Susanne R. Meyer
    Jörg B. Engel
    Johannes Dietl
    Arnd Honig
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 905 - 914
  • [2] Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer
    Hahne, Jens C.
    Schmidt, Heike
    Meyer, Susanne R.
    Engel, Joerg B.
    Dietl, Johannes
    Honig, Arnd
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (06) : 905 - 914
  • [3] Blockade of EGFR and HER3 enhances PI3K/Akt antitumor activity in triple negative breast cancer
    Scaltriti, Maurizio
    Tao, Jessica
    Castel, Pau
    Radosevic-Robin, Nina
    Elkabets, Moshe
    Auricchio, Neil
    Juric, Dejan
    Penault-Llorca, Frederique
    Baselga, Jose
    CANCER RESEARCH, 2014, 74 (19)
  • [4] Combined blockade of PI3K/AKT and EGFR/HER3 enhances antitumor activity in triple negative breast cancer
    Scaltriti, Maurizio
    Tao, Jessica
    Juric, Dejan
    Auricchio, Neil
    Castel, Pau
    Morse, Natasha
    Kim, Phillip
    Singh, Sharat
    Hazra, Saswati
    Hembrough, Todd
    Burrows, Jon
    Baselga, Jose
    CANCER RESEARCH, 2013, 73 (08)
  • [5] Combined PI3K and AURKA inhibition are efficacious in triple-negative breast cancer models
    Van Swearingen, Amanda E. D.
    Sambade, Maria J.
    Sud, Shivani
    Golitz, Brian
    Johnson, Gary L.
    Anders, Carey K.
    CANCER RESEARCH, 2016, 76
  • [6] ANTITUMOR ACTIVITY OF DUAL PI3K AND ER BLOCKADE IN ER POSITIVE BREAST CANCER MODELS
    Tao, J.
    Scaltriti, M.
    Marlow, S.
    Elkabets, M.
    Morse, N.
    Sgroi, D.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 126 - 126
  • [7] Targeting PI3K/AKT pathway in triple-negative breast cancer
    Delaloge, Suzette
    DeForceville, Louise
    LANCET ONCOLOGY, 2017, 18 (10): : 1293 - 1294
  • [8] Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
    Prvanovic, Mirjana
    Nedeljkovic, Milica
    Tanic, Nasta
    Tomic, Tijana
    Terzic, Tanja
    Milovanovic, Zorka
    Maksimovic, Zlatko
    Tanic, Nikola
    LIFE-BASEL, 2021, 11 (11):
  • [9] In vitro profiling of the potent and selective PI3K inhibitor AEZS-126
    Seipelt, Irene
    Gerlach, Matthias
    Blumenstein, Lars
    Mueller, Gilbert
    Teifel, Michael
    Polymeropoulos, Emmanuel
    Guenther, Eckhard
    CANCER RESEARCH, 2009, 69
  • [10] Antitumor activity of a dual PI3K and HDAC inhibitor in hematologic cancer models
    Bao, Rudi
    Wang, Dagong
    Qu, Hui
    Yin, Ling
    Xu, Guang-Xin
    DellaRocca, Steven
    Borek, Mylissa
    Atoyan, Ruzanna
    Forrester, Jeffrey
    Samson, Maria
    Wang, Jing
    Zhai, Hai-Xaio
    Chan, Mendy
    Lai, Cheng-Jung
    Cai, Xiong
    Qian, Changgeng
    CANCER RESEARCH, 2011, 71
12345